A patient is described who had severe orthostatic
Introduction
Idiopathic postural hypotension was first described by Bradbury and Eggleston in 1925 and they suggested that it was caused by paralysis of the sympathetic vasoconstrictor nerve endings. A variety of systemic diseases affecting the central and peripheral nervous system have subsequently been documented as causes of orthostatic hypotension and it is now known that the final factor in causing orthostatic hypotension is a failure of noradrenaline release from vasoconstrictor nerve endings (Bannister, Sever and Gross, 1977) .
In the following case report, no definite cause for the orthostatic hypotension was found during life but post-mortem revealed a possible answer.
Case history
A 73-year-old male retired army officer had a sudden onset of persistent dizziness on standing upright in October 1976 and this progressed to losses of consciousness on standing up, over a period of a few days. These (Ivy, 1961; Siemsen and Meister, 1963; Lhermitte et al., 1970; Park et , 1977) . Initially it was thought that he had true idiopathic orthostatic hypotension but the rapid onset and deterioration of symptoms is unlike the cases originally described by Bradbury and Eggleston (1925) and the absence of central nervous system signs is unlike the cases described by Shy and Drager in 1960 . The presence of weight loss, muscle wasting and a mixed peripheral neuropathy suggested a diagnosis of carcinomatous neuropathy (Henson, Russell and Wilkinson, 1954) (Demanet, 1976) before and after monoamine oxidase therapy, to see if a therapeutic response could be obtained (Nanda, Johnson and Keogh, 1976) . Tyramine is an indirect sympathomimetic amine and is effective only in patients with relatively intact sympathetic nerve endings. Monoamine oxidase inhibitor therapy was given in an attempt to potentiate the effect of any noradrenaline released by the tyramine. Tyramine hydrochloride powder was obtained by the pharmacy and made up into solution or into 10-mg capsules. The first tyramine test using infusions <1000 ,ug/min achieved no significant increase in the supine or standing blood pressure. The second tyramine infusion following therapy for one week with tranylcypromine was more successful. The supine and standing blood pressures were higher than before tranylcypromine therapy and were further elevated by an infusion of tyramine 100 jig/min for 10 min and this elevation was maintained for one hour. This therapy was therefore continued orally in addition to the fludrocortisone and potassium therapy which is thought to be of benefit by causing volume expansion. However, the beneficial effect of this combined therapy was only sustained for a few weeks, a result similar to the effect of other forms of therapy in the treatment of orthostatic hypotension (Bannister, Ardill and Fenton, 1969) .
The finding of a bronchial oat cell carcinoma at post-mortem suggested that this has been the cause of the patient's severe orthostatic hypotension and considering the clinical course of the hypotension it is likely that this was a non-metastatic rather than a metastatic complication.
Conclusion
The patient had an autonomic and peripheral neuropathy with severe orthostatic hypotension which responded poorly to various therapeutic manoeuvres. Initial improvement of the postural hypotension with tyramine and tranylcypromine was not sustained. It is suggested that this patient's severe postural hypotension which was present for 8 months before his death, was a non-metastatic complication of an underlying bronchial oat cell carcinoma, which interfered with reflex vasoconstriction on standing.
